Nath Bio-Genes (India)'s Q4 FY 2025-26 Quarterly Results

Result Summary

• Nath Bio-Genes (India) Ltd reported a 20.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.3%.
• Its expenses for the quarter were down by 22.3% QoQ and 2.8% YoY.
• The net profit decreased 100.6% QoQ and decreased 100.7% YoY.
• The earnings per share (EPS) of Nath Bio-Genes (India) Ltd declined at 0.79 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Nath Bio-Genes (India) Ltd is a company involved in the agricultural sector, primarily focused on the production and distribution of seeds. While specific recent developments for the company are not available, the company's operations typically revolve around providing high-quality seeds to support agricultural productivity. Nath Bio-Genes operates in an industry that is crucial for supporting food security and agricultural development, often impacted by factors such as climate conditions, government policies, and technological advancements in agriculture.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Nath Bio-Genes reported a total income of ₹53.97 crores. This represents a decrease of 20.3% compared to the previous quarter (Q3FY26) where the total income was ₹67.69 crores. Year-over-year (YoY), the total income also saw a decline of 3.3% from ₹55.83 crores in Q4FY25. The decrease in total income on both a QoQ and YoY basis suggests a notable reduction in revenue generation for the quarter under review.

Profitability

For Q4FY26, Nath Bio-Genes recorded a profit before tax of ₹2.49 crores, showing a slight QoQ increase of 0.4% from ₹2.48 crores in Q3FY26. Year-over-year, this represents a substantial increase of 58.6% from ₹1.57 crores in Q4FY25. The tax expense for Q4FY26 was ₹2.50 crores, which is a significant increase of 187.4% QoQ and 296.8% YoY. Consequently, the company reported a loss after tax of ₹0.01 crores in Q4FY26, a sharp decline from a profit after tax of ₹1.60 crores in Q3FY26 and ₹1.48 crores in Q4FY25.

Operating Metrics

The earnings per share (EPS) for Nath Bio-Genes in Q4FY26 was negative at ₹-0.79, compared to ₹0.84 in Q3FY26 and ₹0.42 in Q4FY25. This reflects a QoQ decrease of 194.0% and a YoY decrease of 288.1%. These metrics indicate a deterioration in shareholder value over the quarter and year. Total expenses for Q4FY26 were ₹52.74 crores, marking a decrease of 22.3% QoQ from ₹67.90 crores in Q3FY26 and a 2.8% decrease YoY from ₹54.26 crores in Q4FY25. The reduction in expenses did not offset the decline in income, leading to the observed financial results.